vorasidenib
AmoyDx, Servier Partner to Develop CDx for Diffuse Glioma in China
The companies will develop a test to detect isocitrate dehydrogenase 1 and 2 gene mutations for use with Servier's investigational drug vorasidenib.
Servier to Seek FDA, EMA Approvals for Vorasidenib in IDH-Mutant Glioma
The firm plans to submit data from the Phase III INDIGO study to regulators in the US and Europe by the end of 2023 and in early 2024, respectively.